Thomas Martin

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/691102/thomas-martin-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

194	9,228	53	84
papers	citations	h-index	g-index
197	10,321 ext. citations	4	6.47
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
194	Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users. <i>Journal of Analytical Toxicology</i> , 2020 , 44, 651-660	2.9	5
193	Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. <i>Translational Psychiatry</i> , 2020 , 10, 71	8.6	22
192	Pyrrolidinyl Synthetic Cathinones EPHP and 4F-EPVP Metabolite Profiling Using Human Hepatocyte Incubations. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	1
191	Correlation of creatinine- and specific gravity-normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users. <i>Drug Testing and Analysis</i> , 2019 , 11, 968-975	3.5	11
190	Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2018 , 36, 304-312	2.6	9
189	Optimization of recombinant Eglucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2018 , 10, 518-529	3.5	15
188	Decreased Cannabinoid CB Receptors in Male Tobacco Smokers Examined With Positron Emission Tomography. <i>Biological Psychiatry</i> , 2018 , 84, 715-721	7.9	14
187	Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018 , 157, 27-35	3.5	14
186	Recent Self-Reported Cannabis Use Is Associated With the Biometrics of Delta-9-Tetrahydrocannabinol. <i>Journal of Studies on Alcohol and Drugs</i> , 2018 , 79, 441-446	1.9	14
185	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. <i>PLoS ONE</i> , 2018 , 13, e0190768	3.7	58
184	Quantification of ethyl glucuronide, ethyl sulfate, nicotine, and its metabolites in human fetal liver and placenta. <i>Forensic Toxicology</i> , 2018 , 36, 102-112	2.6	3
183	Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018 , 367, 543-550	4.7	10
182	In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). <i>Forensic Toxicology</i> , 2017 , 35, 20-32	2.6	30
181	Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration. <i>Journal of Applied Toxicology</i> , 2017 , 37, 922-932	4.1	24
180	Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. <i>AAPS Journal</i> , 2017 , 19, 568-577	3.7	19
179	Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Eretrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration. <i>Clinical Chemistry</i> , 2017 , 63, 647-662	5.5	29
178	Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. <i>Drug and Alcohol Dependence</i> , 2017 , 175, 67-76	4.9	53

(2016-2017)

177	The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study. <i>European Neuropsychopharmacology</i> , 2017 , 27, 679-690	1.2	9	
176	On-site oral fluid 9 -tetrahydrocannabinol (THC) screening after controlled smoked, vaporized, and oral cannabis administration. <i>Forensic Toxicology</i> , 2017 , 35, 133-145	2.6	8	
175	Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. <i>Clinical Chemistry</i> , 2017 , 63, 1008-1021	5.5	36	
174	In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2017 , 35, 252-262	2.6	7	
173	Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs. <i>Current Topics in Behavioral Neurosciences</i> , 2017 , 32, 93-117	3.4	99	
172	Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. <i>Clinical Chemistry</i> , 2017 , 63, 1753-1763	5.5	9	
171	Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. <i>Drug and Alcohol Dependence</i> , 2017 , 180, 68-75	4.9	28	
170	Tobacco Exposure and Conditional Weight-for-Length Gain by 2 Years of Age. <i>Journal of Pediatric Psychology</i> , 2017 , 42, 679-688	3.2	5	
169	Long-term stability of cannabinoids in oral fluid after controlled cannabis administration. <i>Drug Testing and Analysis</i> , 2017 , 9, 143-147	3.5	23	
168	Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. <i>Neuropsychopharmacology</i> , 2017 , 42, 649-660	8.7	20	
167	Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. <i>Drug Testing and Analysis</i> , 2017 , 9, 905-915	3.5	55	
166	Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. <i>Current Neuropharmacology</i> , 2017 , 15, 682-691	7.6	29	
165	In vitro stability of free and glucuronidated cannabinoids in blood and plasma collected in plastic gray-top sodium fluoride tubes following controlled smoked cannabis. <i>Forensic Toxicology</i> , 2016 , 34, 179-185	2.6	6	
164	4-Methoxy-EPVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2016 , 34, 61-75	2.6	40	
163	Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips. <i>Analytical and Bioanalytical Chemistry</i> , 2016 , 408, 6461-71	4.4	37	
162	Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases. <i>Drug Metabolism Reviews</i> , 2016 , 48, 237-65	7	46	
161	Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016 , 1451, 97-106	4.5	5	
160	Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016 , 1453, 34-42	4.5	44	

159	Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance. <i>Drug Testing and Analysis</i> , 2016 , 8, 682-9	3.5	26	
158	Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2016 , 30, 1067-78	2.2	49	
157	Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. <i>Addiction Biology</i> , 2016 , 21, 339-47	4.6	76	
156	School-Aged Outcomes following Prenatal Methamphetamine Exposure: 7.5-Year Follow-Up from the Infant Development, Environment, and Lifestyle Study. <i>Journal of Pediatrics</i> , 2016 , 170, 34-8.e1	3.6	20	
155	Effect of Blood Collection Time on Measured B -Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy. <i>Clinical Chemistry</i> , 2016 , 62, 367-77	5.5	44	
154	Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. <i>Forensic Science International</i> , 2016 , 260, 95-101	2.6	19	
153	In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22. <i>AAPS Journal</i> , 2016 , 18, 455-64	3.7	45	
152	Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. <i>Drug and Alcohol Dependence</i> , 2016 , 161, 298-306	4.9	53	
151	In vitro, in vivo and in silico metabolic profiling of Epyrrolidinopentiothiophenone, a novel thiophene stimulant. <i>Bioanalysis</i> , 2016 , 8, 65-82	2.1	40	
150	High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. <i>Clinical Chemistry</i> , 2016 , 62, 157-69	5.5	62	
149	Free and Glucuronide Whole Blood CannabinoidsRPharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. <i>Clinical Chemistry</i> , 2016 , 62, 1579-1592	5.5	93	
148	MDMA Impairs Response to Water Intake in Healthy Volunteers. <i>Advances in Pharmacological Sciences</i> , 2016 , 2016, 2175896	4.9	4	
147	A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. <i>Journal of Pain Research</i> , 2016 , 9, 587-98	2.9	29	
146	Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. <i>Drug Testing and Analysis</i> , 2016 , 8, 779-91	3.5	27	
145	Cannabis effects on driving longitudinal control with and without alcohol. <i>Journal of Applied Toxicology</i> , 2016 , 36, 1418-29	4.1	56	
144	Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. <i>Drug Testing and Analysis</i> , 2016 , 8, 690-701	3.5	30	
143	Naloxone and Metabolites Quantification in Cord Blood of Prenatally Exposed Newborns and Correlations with Maternal Concentrations. <i>AJP Reports</i> , 2016 , 6, e385-e390	1.2	7	
142	Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. <i>Forensic Toxicology</i> , 2016 , 34, 256-267	2.6	19	

(2015-2016)

141	First metabolic profile of PV8, a novel synthetic cathinone, in human hepatocytes and urine by high-resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2016 , 408, 4845-56	4.4	34	
140	Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [C]CURB. <i>Biological Psychiatry</i> , 2016 , 80, 691-701	7.9	37	
139	Simultaneous quantification of buprenorphine, naloxone and phase I and II metabolites in plasma and breastmilk by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016 , 1446, 70-7	4.5	16	
138	Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. <i>Drug and Alcohol Dependence</i> , 2016 , 163, 116-25	4.9	14	
137	Drug Recognition Expert (DRE) examination characteristics of cannabis impairment. <i>Accident Analysis and Prevention</i> , 2016 , 92, 219-29	6.1	31	
136	Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry. <i>AAPS Journal</i> , 2016 , 18, 1489-1499	3.7	55	
135	Cocaine and benzoylecgonine oral fluid on-site screening and confirmation. <i>Drug Testing and Analysis</i> , 2016 , 8, 296-303	3.5	10	
134	Clinical sensitivity and specificity of meconium fatty acid ethyl ester, ethyl glucuronide, and ethyl sulfate for detecting maternal drinking during pregnancy. <i>Clinical Chemistry</i> , 2015 , 61, 523-32	5.5	60	
133	Antiretroviral Drugs in Meconium: Detection for Different Gestational Periods of Exposure. <i>Journal of Pediatrics</i> , 2015 , 167, 305-11.e3	3.6	5	
132	Physiological reactivity during object manipulation among cigarette-exposed infants at 9 months of age. <i>Neurotoxicology and Teratology</i> , 2015 , 48, 64-8	3.9	О	
131	Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1239-46	4	54	
130	Cannabis effects on driving lateral control with and without alcohol. <i>Drug and Alcohol Dependence</i> , 2015 , 154, 25-37	4.9	137	
129	Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching. <i>Journal of Chromatography A</i> , 2015 , 1397, 32-42	4.5	92	
128	Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. <i>Drug Metabolism Reviews</i> , 2015 , 47, 124-74	7	79	
127	Cannabinoid disposition in oral fluid after controlled vaporizer administration with and without alcohol. <i>Forensic Toxicology</i> , 2015 , 33, 260-278	2.6	11	
126	Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2015 , 33, 295-310	2.6	55	
125	Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA. <i>AAPS Journal</i> , 2015 , 17, 660-77	3.7	85	
124	Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users. <i>Journal of Analytical Toxicology</i> , 2015 , 39, 580-7	2.9	30	

123	Cocaine and metabolite concentrations in DBS and venous blood after controlled intravenous cocaine administration. <i>Bioanalysis</i> , 2015 , 7, 2041-56	2.1	20
122	Quantification of six cannabinoids and metabolites in oral fluid by liquid chromatography-tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2015 , 7, 684-94	3.5	41
121	Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking. <i>Drug Testing and Analysis</i> , 2015 , 7, 494-501	3.5	12
120	Morphine and codeine in oral fluid after controlled poppy seed administration. <i>Drug Testing and Analysis</i> , 2015 , 7, 586-91	3.5	12
119	High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. <i>Drug</i>	3.5	36
118	Testing and Analysis, 2015, 7, 187-98 Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. <i>Drug Testing and Analysis</i> , 2015, 7, 483-93	3.5	27
117	Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. <i>Drug Testing and Analysis</i> , 2015 , 7, 467-74	3.5	28
116	Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2015 , 407, 883-97	4.4	105
115	Oral fluid with three modes of collection and plasma methamphetamine and amphetamine enantiomer concentrations after controlled intranasal l-methamphetamine administration. <i>Drug Testing and Analysis</i> , 2015 , 7, 877-83	3.5	11
114	Validation of an ELISA Synthetic Cannabinoids Urine Assay. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 661-	93.2	18
113	Smoked cannabisRpsychomotor and neurocognitive effects in occasional and frequent smokers. Journal of Analytical Toxicology, 2015 , 39, 251-61	2.9	90
112	Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2015 , 407, 4639-48	4.4	14
111	Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. <i>Clinical Chemistry</i> , 2015 , 61, 850-69	5.5	85
110	Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 423-34	5.9	25
109	Impact of oral fluid collection device on cannabinoid stability following smoked cannabis. <i>Drug Testing and Analysis</i> , 2015 , 7, 114-20	3.5	18
108	Simultaneous plasma and oral fluid morphine and codeine concentrations after controlled administration of poppy seeds with known opiate content. <i>Forensic Toxicology</i> , 2015 , 33, 235-243	2.6	9
107	Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry. <i>Forensic Toxicology</i> , 2015 , 33, 202-212	2.6	9
106	Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 1763-80	4.4	93

105	Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology. <i>Drug Testing and Analysis</i> , 2014 , 6, 728-38	3.5	47
104	3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry. <i>Analytica Chimica Acta</i> , 2014 , 827, 54-63	6.6	37
103	Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. <i>Forensic Science International</i> , 2014 , 241, 27-34	2.6	42
102	Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. <i>Forensic Science International</i> , 2014 , 241, 87-90	2.6	26
101	Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2014 , 1327, 105-17	4.5	86
100	Validation of a novel method to identify in utero ethanol exposure: simultaneous meconium extraction of fatty acid ethyl esters, ethyl glucuronide, and ethyl sulfate followed by LC-MS/MS quantification. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 1945-55	4.4	29
99	Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. <i>Drug and Alcohol Dependence</i> , 2014 , 144, 12-41	4.9	453
98	Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?. <i>Clinical Chemistry</i> , 2014 , 60, 361-	-7 ⁵ 2 ⁵	29
97	Rapid quantitative chiral amphetamines liquid chromatography-tandem mass spectrometry: method in plasma and oral fluid with a cost-effective chiral derivatizing reagent. <i>Journal of Chromatography A</i> , 2014 , 1358, 68-74	4.5	34
96	Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration. <i>Journal of Analytical Toxicology</i> , 2014 , 38, 524-7	2.9	12
95	Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. <i>Clinical Chemistry</i> , 2014 , 60, 631-43	5.5	95
94	Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder. <i>Schizophrenia Research</i> , 2014 , 152, 315-6	3.6	3
93	Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 4117-28	4.4	33
92	Maternal smoking during pregnancy and infant stress response: test of a prenatal programming hypothesis. <i>Psychoneuroendocrinology</i> , 2014 , 48, 29-40	5	78
91	Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers. <i>PLoS ONE</i> , 2014 , 9, e113694	3.7	32
90	Quantification of cocaine and metabolites in exhaled breath by liquid chromatography-high-resolution mass spectrometry following controlled administration of intravenous cocaine. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 6213-23	4.4	23
89	In reply. <i>Clinical Chemistry</i> , 2014 , 60, 1236-7	5.5	1
88	Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. <i>American Journal on Addictions</i> , 2014 , 23, 234-42	3.7	36

87	Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. <i>Drug Testing and Analysis</i> , 2014 , 6, 1002-10	3.5	27
86	Commentary. Clinical Chemistry, 2014, 60, 1484-5	5.5	
85	Re: "trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999-2010". <i>American Journal of Epidemiology</i> , 2014 , 180, 862-3	3.8	7
84	Current knowledge on cannabinoids in oral fluid. <i>Drug Testing and Analysis</i> , 2014 , 6, 88-111	3.5	61
83	In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 785-92	4.4	15
82	3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 587-99	4.4	19
81	Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 7269-79	4.4	23
80	11-Nor-9-carboxy- 9 -tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 6019-27	4.4	18
79	Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 4679-89	4.4	29
78	First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. <i>AAPS Journal</i> , 2013 , 15, 1091-8	3.7	67
77	Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 9437-48	4.4	97
76	Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 8451-61	4.4	38
75	Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?. <i>Drug and Alcohol Dependence</i> , 2013 , 130, 68-76	4.9	26
74	Simultaneous quantification of (Þ)-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol and cannabinol in oral fluid by microflow-liquid chromatography-high resolution mass spectrometry. <i>Journal of Chromatography A</i> , 2013 , 1297, 123-30	4.5	37
73	Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. <i>Analytical Chemistry</i> , 2013 , 85, 3730-8	7.8	102
72	Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 4067-76	4.4	16
71	Impact of prolonged cannabinoid excretion in chronic daily cannabis smokersRblood on per se drugged driving laws. <i>Clinical Chemistry</i> , 2013 , 59, 519-26	5.5	106
70	Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. <i>American Journal on Addictions</i> , 2013 , 22, 510-4	3.7	20

(2010-2013)

69	In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis. <i>Clinical Chemistry</i> , 2013 , 59, 1108-17	5.5	37
68	Simultaneous quantification of nicotine, cotinine, trans-3Rhydroxycotinine, norcotinine and mecamylamine in human urine by liquid chromatography-tandem mass spectrometry. <i>Clinica Chimica Acta</i> , 2012 , 413, 978-84	6.2	23
67	Predictive model accuracy in estimating last 9 -tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. <i>Drug and Alcohol Dependence</i> , 2012 , 125, 313-9	4.9	33
66	Psychomotor performance, subjective and physiological effects and whole blood Eterahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. <i>Journal of Analytical Toxicology</i> , 2012 , 36, 405-12	2.9	71
65	CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men. <i>American Journal of Drug and Alcohol Abuse</i> , 2012 , 38, 114-9	3.7	16
64	Cannabis in sport: anti-doping perspective. <i>Sports Medicine</i> , 2011 , 41, 949-66	10.6	49
63	Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. <i>Addiction</i> , 2011 , 106, 499-506	4.6	60
62	Simultaneous analysis of buprenorphine, methadone, cocaine, opiates and nicotine metabolites in sweat by liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011 , 400, 69-78	4.4	37
61	Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration. <i>Analytical and Bioanalytical Chemistry</i> , 2011 , 401, 599-607	4.4	24
60	Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011 , 401, 1273-83	3 ^{4·4}	85
59	Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. <i>Clinical Chemistry</i> , 2011 , 57, 1127-36	5.5	62
58	Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. <i>Clinical Chemistry</i> , 2011 , 57, 449-58	5.5	37
57	Oral fluid testing: promises and pitfalls. <i>Clinical Chemistry</i> , 2011 , 57, 805-10	5.5	39
56	Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. <i>Clinical Chemistry</i> , 2011 , 57, 1406-14	5.5	115
55	Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. <i>Addiction</i> , 2010 , 105, 2151-9	4.6	25
54	Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. <i>Clinical Chemistry</i> , 2010 , 56, 1442-50	5.5	85
53	Umbilical cord monitoring of in utero drug exposure to buprenorphine and correlation with maternal dose and neonatal outcomes. <i>Journal of Analytical Toxicology</i> , 2010 , 34, 498-505	2.9	31
52	Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. <i>Clinical Chemistry</i> , 2010 , 56, 1261-9	5.5	37

51	Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 397, 603-11	4.4	32
50	Effect of hydrolysis on identifying prenatal cannabis exposure. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 397, 2335-47	4.4	24
49	High-throughput simultaneous analysis of buprenorphine, methadone, cocaine, opiates, nicotine, and metabolites in oral fluid by liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 398, 915-24	4.4	50
48	Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatum. <i>Neurotoxicity Research</i> , 2010 , 18, 200-9	4.3	5
47	Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences,	3.2	20
46	2010 , 878, 13-20 Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. <i>Journal of Analytical Toxicology</i> , 2009 , 33, 469-77	2.9	78
45	Simultaneous and sensitive measurement of nicotine, cotinine, trans-3Rhydroxycotinine and norcotinine in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 3537-42	3.2	41
44	Simultaneous quantification of nicotine, opioids, cocaine, and metabolites in human fetal postmortem brain by liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2009 , 393, 1957-65	4.4	26
43	A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. <i>Analytical and Bioanalytical Chemistry</i> , 2009 , 393, 1977-90	4.4	55
42	Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2009 , 394, 513-22	4.4	17
41	Optimization and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of nicotine, cotinine, trans-3Rhydroxycotinine and norcotinine in human oral fluid. <i>Analytical and Bioanalytical Chemistry</i> , 2009 , 395, 2349-57	4.4	31
40	Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?. <i>Addiction</i> , 2009 , 104, 2041-8	4.6	77
39	Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine-glucuronide and norbuprenorphine-glucuronide in human umbilical cord by liquid chromatography tandem mass spectrometry. <i>Forensic Science International</i> , 2009 , 188, 144-51	2.6	24
38	Development and validation of a liquid chromatography mass spectrometry assay for the simultaneous quantification of methadone, cocaine, opiates and metabolites in human umbilical cord. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009,	3.2	25
37	Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. <i>Drug and Alcohol Dependence</i> , 2009 , 105, 24-32	4.9	86
36	Oral fluid testing for drugs of abuse. <i>Clinical Chemistry</i> , 2009 , 55, 1910-31	5.5	298
35	Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing. <i>Clinical Chemistry</i> , 2009 , 55, 1188-95	5.5	44
34	Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. <i>Clinical Chemistry</i> , 2008 , 54, 172-80	5.5	37

33	Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. <i>Journal of Analytical Toxicology</i> , 2008 , 32, 562-9	2.9	78
32	Development and validation of a liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for simultaneous analysis of 10 amphetamine-, methamphetamine- and 3,4-methylenedioxymethamphetamine-related (MDMA) analytes in human	3.2	33
31	Development and validation of a solid-phase extraction gas chromatography-mass spectrometry method for the simultaneous quantification of methadone, heroin, cocaine and metabolites in sweat. <i>Analytical and Bioanalytical Chemistry</i> , 2008 , 392, 115-27	4.4	42
30	Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of buprenorphine, norbuprenorphine, and metabolites in human urine. <i>Analytical and Bioanalytical Chemistry</i> , 2008 , 392, 903-11	4.4	15
29	Quantification of nicotine, cotinine, trans-3Rhydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography/tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008 , 863, 107-14	3.2	48
28	A validated gas chromatographic-electron impact ionization mass spectrometric method for methamphetamine, methylenedioxymethamphetamine (MDMA), and metabolites in mouse plasma and brain. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences,	3.2	14
27	Excretion of Delta9-tetrahydrocannabinol in sweat. <i>Forensic Science International</i> , 2008 , 174, 173-7	2.6	44
26	Cocaine and metabolites urinary excretion after controlled smoked administration. <i>Journal of Analytical Toxicology</i> , 2007 , 31, 462-8	2.9	35
25	Human cannabinoid pharmacokinetics. <i>Chemistry and Biodiversity</i> , 2007 , 4, 1770-804	2.5	588
24	Development and validation of a disk solid phase extraction and gas chromatography-mass spectrometry method for MDMA, MDA, HMMA, HMA, MDEA, methamphetamine and amphetamine in sweat. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> ,	3.2	29
23	Methamphetamine disposition in oral fluid, plasma, and urine. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1098, 104-21	6.5	59
22	Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. <i>Psychopharmacology</i> , 2007 , 194, 505-15	4.7	121
21	Cannabinoid concentrations in hair from documented cannabis users. <i>Forensic Science International</i> , 2007 , 169, 129-36	2.6	80
20	Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients. <i>Drug and Alcohol Dependence</i> , 2007 , 87, 258-67	4.9	67
19	A validated method for the determination of nicotine, cotinine, trans-3Rhydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2006 , 41, 815-21	2.2	37
18	A validated positive chemical ionization GC/MS method for the identification and quantification of amphetamine, opiates, cocaine, and metabolites in human postmortem brain. <i>Journal of Mass Spectrometry</i> , 2006 , 41, 175-84	2.2	22
17	Sensitive gas chromatography-mass spectrometry method for simultaneous measurement of MDEA, MDMA, and metabolites HMA, MDA, and HMMA in human urine. <i>Clinical Chemistry</i> , 2006 , 52, 172	! § :34	23
16	Modern analytical technologies for the detection of drug abuse and doping. <i>Drug Discovery Today: Technologies</i> , 2006 , 3, 49-57	7.1	19

15	Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 540-4	3.2	37
14	Simultaneous determination of nicotine, cotinine, norcotinine, and trans-3Rhydroxycotinine in human oral fluid using solid phase extraction and gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005 , 814, 233-40	3.2	53
13	Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. <i>Journal of Chromatography</i>	3.2	33
12	Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine-3-beta-D-glucuronide and norbuprenorphine-3-beta-D-glucuronide in human plasma. <i>Journal of Mass Spectrometry</i> , 2005 , 40, 70-4	2.2	34
11	LC-ESI-MS/MS analysis for the quantification of morphine, codeine, morphine-3-beta-D-glucuronide, morphine-6-beta-D-glucuronide, and codeine-6-beta-D-glucuronide in human urine. <i>Journal of Mass Spectrometry</i> , 2005 , 40, 1412-6	2.2	50
10	Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations. <i>Clinical Chemistry</i> , 2005 , 51, 2289-95	5.5	64
9	Performance characteristics of the Cozart RapiScan Oral Fluid Drug Testing System for opiates in comparison to ELISA and GC/MS following controlled codeine administration. <i>Forensic Science International</i> , 2004 , 141, 41-8	2.6	37
8	Validated method for the simultaneous determination of Delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography-mass spectrometry with positive chemical ionization. <i>Journal of Chromatography</i>	3.2	69
7	Urine drug testing for opioids, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2003 , 17, 1665-70	2.2	96
6	Sensitivity and specificity of the Cozart microplate EIA cocaine oral fluid at proposed screening and confirmation cutoffs. <i>Clinical Chemistry</i> , 2003 , 49, 1498-503	5.5	19
5	Drug abuseß smallest victims: in utero drug exposure. Forensic Science International, 2002, 128, 20-30	2.6	117
4	A study of peptidepeptide interaction by matrix-assisted laser desorption/ionization. <i>Journal of the American Society for Mass Spectrometry</i> , 2001 , 12, 88-96	3.5	69
3	Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. <i>Archives of General Psychiatry</i> , 2001 , 58, 322-8		371
2	Identification of hydrocodone in human urine following controlled codeine administration. <i>Journal of Analytical Toxicology</i> , 2000 , 24, 530-5	2.9	67
1	Detection times of marijuana metabolites in urine by immunoassay and GC-MS. <i>Journal of Analytical Toxicology</i> , 1995 , 19, 443-9	2.9	93